{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001576280","name":"Guardant Health, Inc.","summary":"Guardant Health is a precision oncology company offering blood and tissue-based cancer tests powered by its Smart Platform, which integrates methylation, genomic, epigenomic, and RNA-based data with AI analytics. Key products include Guardant360 CDx (FDA-approved liquid biopsy companion diagnostic), Guardant360 Liquid, Guardant360 Tissue, Guardant Reveal (MRD detection and therapy response monitoring), Shield (FDA-approved blood test for colorectal cancer screening), and GuardantINFINITY. The company serves clinical and biopharmaceutical markets and also offers GuardantINFORM, an in-silico research platform for drug development.","people":[],"products":[{"name":"Guardant360 CDx","type":"service","description":"FDA-approved 74-gene comprehensive liquid biopsy test for tumor mutation profiling and companion diagnostic for NSCLC, colorectal, and breast cancer."},{"name":"Guardant360 Liquid","type":"service","description":"Blood-based test measuring 740+ genes to support guideline-recommended biomarkers for advanced-stage cancer therapy selection, powered by the Smart Platform."},{"name":"Guardant360 Tissue","type":"service","description":"Molecular profiling test for tumor tissue incorporating comprehensive multiomics analysis including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data."},{"name":"Guardant Reveal","type":"service","description":"Tissue-free blood test for minimal residual disease detection, recurrence monitoring, and late-stage therapy response monitoring in solid tumor patients."},{"name":"Shield","type":"service","description":"FDA-approved blood test for primary colorectal cancer screening in adults 45+; first blood-based CRC screening test meeting Medicare coverage requirements."},{"name":"GuardantINFINITY","type":"service","description":"Blood test powered by the Smart Platform providing multi-dimensional insights into tumor molecular profiles and immune response for cancer research."},{"name":"GuardantOMNI","type":"service","description":"Blood test for advanced-stage cancer used in collaboration with biopharmaceutical companies in clinical studies."},{"name":"GuardantINFORM","type":"platform","description":"In-silico research platform using AI-enabled analytics to help biopharmaceutical companies accelerate precision oncology drug development."},{"name":"Smart Platform","type":"platform","description":"Proprietary platform utilizing methylation technology with genomic, epigenomic, and RNA-based data, advanced algorithms, and the InfinityAI learning engine."},{"name":"Shield MCD","type":"service","description":"Multi-cancer detection extension of the Shield blood test; granted FDA Breakthrough Device designation."}],"partnerships":[{"partner_name":"Biopharmaceutical companies (unspecified)","partnership_type":"development","description":"Collaborate on clinical studies using Guardant tests including GuardantINFINITY and GuardantOMNI to advance cancer research and therapy development.","start_date":null},{"partner_name":"Electronic medical record partners (unspecified)","partnership_type":"strategic","description":"Collaborations to provide seamless customer experiences through EMR integration.","start_date":null},{"partner_name":"Cancer centers and research organizations (unspecified)","partnership_type":"strategic","description":"Partnerships to establish clinical utility for tests and create new testing opportunities related to emerging therapies.","start_date":null},{"partner_name":"Laboratory companies in Europe and Asia (unspecified)","partnership_type":"strategic","description":"Partnerships with distributors and laboratory companies to drive global commercialization of products.","start_date":null}],"affiliations":[],"origin":{"leaf":"e2733388cffd573ef6ebca79a849a3c3a7362571e35fc3aaec555c0732c84be2","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"58c76f49d378ab9233b007b39fc1c693d237d343415e9521f44c10a4613eff51","parent":"7940c05e8dad5081409b01641e7e959f4c7315672262da81c7e1a41028ccaec8","source":"0001576280-26-000013","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":83,"hourly_limit":500,"remaining":417,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}